BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31241144)

  • 1. Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations.
    Claw KG; Beans JA; Lee SB; Avey JP; Stapleton PA; Scherer SE; El-Boraie A; Tyndale RF; Nickerson DA; Dillard DA; Thummel KE; Robinson RF
    Nicotine Tob Res; 2020 May; 22(6):910-918. PubMed ID: 31241144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
    Binnington MJ; Zhu AZ; Renner CC; Lanier AP; Hatsukami DK; Benowitz NL; Tyndale RF
    Pharmacogenet Genomics; 2012 Jun; 22(6):429-40. PubMed ID: 22569203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations.
    Twesigomwe D; Drögemöller BI; Wright GEB; Adebamowo C; Agongo G; Boua PR; Matshaba M; Paximadis M; Ramsay M; Simo G; Simuunza MC; Tiemessen CT; Lombard Z; Hazelhurst S
    Clin Pharmacol Ther; 2024 Mar; 115(3):576-594. PubMed ID: 38049200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.
    Tanner JA; Henderson JA; Buchwald D; Howard BV; Nez Henderson P; Tyndale RF
    Pharmacogenet Genomics; 2017 May; 27(5):169-178. PubMed ID: 28181923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic Optimization of Smoking Cessation Treatment.
    Chenoweth MJ; Tyndale RF
    Trends Pharmacol Sci; 2017 Jan; 38(1):55-66. PubMed ID: 27712845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).
    Chen LS; Bloom AJ; Baker TB; Smith SS; Piper ME; Martinez M; Saccone N; Hatsukami D; Goate A; Bierut L
    Addiction; 2014 Jan; 109(1):128-137. PubMed ID: 24033696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke.
    Schaefer KR; Avey JP; Todd MR; Beans JA; Dillard DA; Shireman LM; Thornton TA; Tyndale RF; Thummel KE; Robinson RF; Claw KG
    Clin Transl Sci; 2021 Nov; 14(6):2474-2486. PubMed ID: 34520119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline.
    Tomaz PRX; Kajita MS; Santos JR; Scholz J; Abe TO; Gaya PV; Krieger JE; Pereira AC; Santos PCJL
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1541-1545. PubMed ID: 31402421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review.
    Jones SK; Wolf BJ; Froeliger B; Wallace K; Carpenter MJ; Alberg AJ
    Nicotine Tob Res; 2022 Mar; 24(5):633-642. PubMed ID: 34478556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers.
    Chenoweth MJ; Sylvestre MP; Contreras G; Novalen M; O'Loughlin J; Tyndale RF
    Drug Alcohol Depend; 2016 Jan; 158():139-46. PubMed ID: 26644138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
    Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
    Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
    Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
    Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries.
    Baurley JW; Edlund CK; Pardamean CI; Conti DV; Krasnow R; Javitz HS; Hops H; Swan GE; Benowitz NL; Bergen AW
    Nicotine Tob Res; 2016 Sep; 18(9):1837-1844. PubMed ID: 27113016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
    Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
    Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.
    Salloum NC; Buchalter ELF; Chanani S; Espejo G; Ismail MS; Laine RO; Nageeb M; Srivastava AB; Trapp N; Trillo L; Vance E; Wenzinger M; Hartz SM; David SP; Chen LS
    Pharmacogenomics; 2018 Jul; 19(10):861-871. PubMed ID: 29914292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation.
    Tran AX; Ho TT; Varghese Gupta S
    J Clin Pharm Ther; 2019 Apr; 44(2):174-179. PubMed ID: 30578565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of CYP2A6 Gene Polymorphism with Smoking Status Among Jordanians: Gender-Related Differences.
    Hammad HM; Imraish A; Azab B; Best AM; Khader YS; Zihlif M
    Curr Drug Metab; 2019; 20(9):765-770. PubMed ID: 31453782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.
    Bloom AJ; Martinez M; Chen LS; Bierut LJ; Murphy SE; Goate A
    PLoS One; 2013; 8(11):e79700. PubMed ID: 24260284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
    Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
    Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.
    Fohner AE; Dalton R; Skagen K; Jackson K; Claw KG; Hopkins SE; Robinson R; Khan BA; Prasad B; Schuetz EG; Nickerson DA; Thornton TA; Dillard DA; Boyer BB; Thummel KE; Woodahl EL
    Clin Transl Sci; 2021 Jul; 14(4):1292-1302. PubMed ID: 33503331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.